AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Stars over Athens: The who’s who at Calcalist's first Israel-Greece conference
2
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
3
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
4
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
5
Oracle CEO: "If we continue on our current trajectory, reaching a valuation of a trillion dollars is inevitable"
More news

Biomed

8 stories about Biomed
תרופות זירת הבריאות

Entera Bio Gives Nasdaq IPO Another Shot

21.05.18|Dror Reich
This is the fourth time since 2014 that the Jerusalem-based biomed company files for an initial public offering on Nasdaq
default image

Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange

29.04.18|Racheli Bindman
Dually listed on Nasdaq and TASE, Opko first submitted a request to delist from the TASE in early April
חממת קנאביס

An Israeli Company Wants to Treat Tourette Syndrome With Cannabis

09.04.18|Lilach Baumer
Therapix Biosciences announced the successful completion of phase 2 clinical trial of its cannabinoid-based drug, conducted at Yale University Monday
נאסד"ק וול סטריט

For the Fourth Time, Entera Bio Tries for Nasdaq IPO

08.01.18|Dror Reich
The Jerusalem-based biomed company plans to raise $55 million, with Oppenheimer & Co. as the sole underwriter
default image

Biomed Company Protalix to Lay Off a Fifth of its Workforce

26.11.17|Dror Reich
The Israel-based NYSE American-listed company is currently undergoing a streamlining process
תרופות טבע גלולות תרופה

Entera Bio Files for Nasdaq IPO

12.11.17|Lilach Baumer
The clinical stage company develops treatments mostly for osteoporosis and bone disorders
קולפלנט דיו ביולוגי

Collplant Takes a Step Towards 3D Organ Printing

17.10.17|Lilach Baumer
The Israel-based company develops collagen-based biological ink for 3D organ printing
default image

IPO Hopeful Entera Bio Moves to Better Position

13.09.17|Dror Reich
Clinical-stage company Entera Bio develops pioneering technology for orphan disease hypoparathyroidism
Previous Articles